Gianfranco Bittar

Dr. Gianfranco Bittar

Baylor St. Luke's Medical Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TZTalal El Zarif
Talal El Zarif
MYMarcel Yibirin
Marcel Yibirin
DGDiana Carolina De Oliveira Gomes
Diana Carolina De Oliveira Gomes
MMMarc Machaalani
Marc Machaalani
Rashad NawfalRashad Nawfal
Rashad Nawfal
NBNizar Bitar
Nizar Bitar
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.

1 January 2025 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
SDSean DeAngelo
Sean DeAngelo
RGRohan Gajjar
Rohan Gajjar
GBGianfranco Bittar
Gianfranco Bittar
BABadri Aryal
Badri Aryal
BPBhannu Pinnam
Bhannu Pinnam
YGYasmeen Golzar
Yasmeen Golzar
DeAngelo S, et al. Int J Heart Fail. 2025 Jan;7(1):21-29. https://doi.org/10.36628/ijhf.2024.0041

2 May 2024 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
DPDae Yong Park
Dae Yong Park
GBGianfranco Bittar
Gianfranco Bittar
MKManoj Kumar
Manoj Kumar
YJYasser Jamil
Yasser Jamil
MNMichael G Nanna
Michael G Nanna
Previous studies conflict on whether seasonal variability exists in atrial fibrillation (AF) admissions, and contemporary studies are lacking. We identified admissions for AF or atrial flutter in the Midwest and Northeast regions of the US from the National Inpatient Database for 2016 to 2020, grouped them into the four seasons (spring, summer, fall, winter), and compared the number of admissions. Subgroup analyses were performed stratified to sex, age, race, AF alone, and geographical regions. A total of 955,320 admissions for AF or atrial flutter occurred. The number of admissions was highest during winter (243,990, 25.5% of the total), followed by fall (239,250, 25.0% of the total), summer (236,910, 24.8% of the total), and spring (235,170, 24.6% of the total). The differences were statistically significant (P < 0.001). An increasing trend in the number of admissions was observed from March to February of the next year (P trend <0.001). Admissions were most common in the winter and least common in the spring in subgroups of both sexes, age ≥65 years, Whites, non-Whites, AF alone, Northeast region, and Midwest region. Contemporary analysis of a national database demonstrates seasonal variability in the number of admissions for AF, with a slight increase observed during the winter.